Headlines about Integra Lifesciences (NASDAQ:IART) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Integra Lifesciences earned a news sentiment score of 0.19 on Accern’s scale. Accern also assigned press coverage about the life sciences company an impact score of 46.2398552045215 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the media headlines that may have impacted Accern’s scoring:
IART has been the topic of several research analyst reports. Zacks Investment Research raised shares of Integra Lifesciences from a “sell” rating to a “hold” rating in a report on Tuesday, December 26th. BidaskClub downgraded shares of Integra Lifesciences from a “sell” rating to a “strong sell” rating in a research note on Friday, January 5th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $52.00 price target on shares of Integra Lifesciences in a research note on Friday, January 5th. TheStreet downgraded shares of Integra Lifesciences from a “b” rating to a “c+” rating in a research note on Thursday, October 26th. Finally, Raymond James Financial reissued a “market perform” rating and issued a $55.00 target price on shares of Integra Lifesciences in a research note on Tuesday, January 2nd. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and three have issued a buy rating to the stock. Integra Lifesciences presently has a consensus rating of “Hold” and an average target price of $52.70.
Shares of Integra Lifesciences (IART) traded down $0.12 during trading on Monday, reaching $52.90. 153,791 shares of the company’s stock traded hands, compared to its average volume of 472,614. The company has a market cap of $4,160.00, a PE ratio of 86.93, a price-to-earnings-growth ratio of 1.70 and a beta of 0.67. Integra Lifesciences has a one year low of $40.51 and a one year high of $56.42. The company has a current ratio of 4.49, a quick ratio of 3.39 and a debt-to-equity ratio of 1.26.
In other Integra Lifesciences news, VP Richard D. Gorelick sold 1,500 shares of the stock in a transaction dated Tuesday, November 14th. The shares were sold at an average price of $47.19, for a total transaction of $70,785.00. Following the completion of the sale, the vice president now directly owns 21,665 shares of the company’s stock, valued at $1,022,371.35. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 21.50% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect Integra Lifesciences (NASDAQ:IART) Stock Price” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of US & international copyright law. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/05/integra-lifesciences-iart-earns-daily-media-sentiment-score-of-0-19.html.
Integra Lifesciences Company Profile
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.